Evaluation of Abuse Deterrent Formulations and Their Technologies | MCPHS CE
The addition of abuse deterrent formulation (ADF) opioids to the market creates the potential to decrease the rates of opioid abuse and related deaths in the United States. This course provides an overview of ADF opioids, when to recommend an ADF opioid, and how to decide what the best opioid option would be based on patient specific factors. This activity is designed to meet the educational needs of pharmacists who work with patients who are at risk for opioid diversion or opioid abuse.
Describe the technologies utilized in current ADF products.
Define an abuse deterrent formulation.
Select an appropriate ADF for a patient for which opioid diversion and/or abuse is a risk.
Identify opioids which are approved as ADFs.
Branson Facemire, PharmD completed both his undergraduate and graduate work at Butler University, where he earned his PharmD in 2021. Following graduation, he accepted a two-year Clinical Operations Fellowship at Novartis Institutes for BioMedical Research (NIBR) in conjunction with MCPHS University. His scholarly interests include opioids and oncology.
Claire E. Jackson, PharmD completed her undergraduate work and earned her Doctor of Pharmacy from Purdue University in 2021. She is currently completing a post-doctoral fellowship with Novartis Institutes for BioMedical Research (NIBR) in conjunction with MCPHS University. She is training to be a clinical scientist through her fellowship program with NIBR, and she is engaged in scholarship and teaching activities as an adjunct professor with MCPHS University.
Free for MCPHS alumni, faculty and staff. For all others the fee is $12.00.
ACPE UAN: 0026-0000-21-011-H05-P| Knowledge-based
Topic Designator: Patient Safety
Contact Hours: 1 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences (MCPHS) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1 contact hours (0.1 CEUs).
Claire Jackson and Branson Facemire hold no financial relationships with ineligible companies, related to the content of this presentation.
Fellowship preceptor Valerie Coppenrath, Pharm D holds no financial relationships with ineligible companies, related to the content of this presentation..
MCPHS staff members hold no financial relationships with ineligible companies, related to the content of this presentation..